Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00096213
NCT00096213CompletedPhase 2

A Phase II Surgical Trial Of Intralesional Resection Of Low-Grade Intracompartmental Chondrosarcoma Of Bone

SWOG Cancer Research Network23 sites in 1 country60 target enrollmentStarted: December 1, 2004Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
60
Locations
23
Primary Endpoint
Probability of local complications
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

RATIONALE: Intralesional resection is a less invasive type of surgery for chondrosarcoma of the bone and may have fewer side effects and improve recovery.

PURPOSE: This phase II trial is studying how well intralesional resection works in treating patients with low-grade chondrosarcoma of the bone.

Detailed Description

OBJECTIVES:

  • Determine the probability of local complications (e.g., fracture, nerve palsy, deep venous thrombosis, unexpected rehospitalization, unanticipated reoperation, or death within 2 years) in patients with suspected low-grade intracompartmental chondrosarcoma of the bone undergoing intralesional resection.
  • Determine the 5-year probability of local recurrence and development of metastatic disease in patients undergoing this procedure.
  • Determine the impact of musculoskeletal tumor reconstruction on the functional status of patients undergoing this procedure.

OUTLINE: This is a multicenter study.

Patients undergo intralesional resection (curettage with high-speed burr). Patients then receive local adjuvant treatment comprising liquid nitrogen, phenol, alcohol, or argon beam to the excision site. The bone cavity is then filled with either polymethyacrylate cement or a bone graft (allograft or homograft). Patients may also have a metal plate installed at the wound site.

Patients are followed every 3 months for 1 year and then every 6 months for 4 years.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •DISEASE CHARACTERISTICS:
  • •Suspected low-grade intracompartmental chondrosarcoma, as defined by the following criteria:
  • •Resorption of prior calcifications (indicated by a change in radiographic appearance over time) AND/OR meets at least 2, but no more than 4, of the following criteria:
  • •Permeative appearance of medullary bone, defined as presence of tumor around 3 sides of a trabecula of normal bone
  • •Endosteal scalloping, defined as > 50% of adjacent cortical thickness
  • •Cortical thickening beyond the thickness of adjacent normal bone
  • •Bone expansion, defined as a circumferential increase in diameter of the bone beyond the adjacent normal bone
  • •Positive (i.e., increased uptake or "hot") bone scan
  • •No cortical disruption and/or soft tissue mass by radiography and CT scan (3 mm cuts are optimal) or MRI
  • •No presumptive axial (spinal) involvement
  • •No multifocal disease by bone scan
  • •PATIENT CHARACTERISTICS:
  • •18 and over
  • •Performance status
  • •Not specified
  • •Life expectancy
  • •Not specified
  • •Hematopoietic
  • •Not specified
  • •Not specified
  • •Not specified
  • •No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission
  • •PRIOR CONCURRENT THERAPY:
  • •Biologic therapy
  • •No prior biologic therapy for this tumor
  • •Chemotherapy
  • •No prior chemotherapy for this tumor
  • •Endocrine therapy
  • •Not specified
  • •Radiotherapy
  • •No prior radiotherapy for this tumor
  • •No prior surgery for this tumor except biopsy*
  • •No concurrent intramedullary fixation NOTE: *Biopsy is not required
  • •No prior investigational anticancer agents for this tumor

Exclusion Criteria

  • Not provided

Arms & Interventions

surgery

Other

intralesional resection

Intervention: conventional surgery (Procedure)

Outcomes

Primary Outcomes

Probability of local complications

Time Frame: two years

Secondary Outcomes

  • Probability of local recurrence and development of metastatic disease(5 years)
  • Impact of musculoskeletal tumor reconstruction on functional status(two years)

Investigators

Sponsor Class
Network
Responsible Party
Sponsor

Study Sites (23)

Loading locations...

Similar Trials

Suspended
Phase 2
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed ChondrosarcomasChondrosarcoma
NCT02008019Centre Leon Berard57
Completed
Not Applicable
Grade 2 Chondrosarcoma Treated by Intralesional Curettage: Follow-up vs ResectionChondrosarcoma, Grade 2
NCT06714773IRCCS Azienda Ospedaliero-Universitaria di Bologna62
Unknown
Phase 3
Comparison of Lobectomy and Segmentectomy for cT1aN0M0 Peripheral NSCLCNon-small Cell Lung Cancer
NCT02481661Zhejiang Cancer Hospital610
Completed
Not Applicable
Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)Melanoma, UvealUveal Melanoma
NCT02874040Institut Curie87
Completed
Phase 4
Comparing Minimal Invasive Surgery en Conventional Total Knee ArthroplastyOsteoarthritis, Knee
NCT02625311Maastricht University Medical Center69